In their recent review (published in Trends in Pharmacological Sciences) Gina Gotthardt, PROXIDRUGS researcher Jan Keiten-Schmitz, and PROXIDRUG PI Stefan Müller discuss how SUMO-signaling and SUMO-targeted ubiquitin ligases (StUbLs) can be exploited to inactivate disease-associated proteins. The review explores the new therapeutic possibilities that this opens within the field of drug discovery utilizing the ubiquitin-proteasome system. Established cancer treatments are harnessing the...

In their publication in Nature Chemical Biology PROXIDRUGS researchers and collaborating universities have discovered a way to prevent...

Targeted protein degradation (TPD) is an emerging therapeutic strategy that hijacks the cellular recycling machinery to degrade and...